Market revenue in 2023 | USD 2,718.7 million |
Market revenue in 2030 | USD 5,787.0 million |
Growth rate | 11.4% (CAGR from 2023 to 2030) |
Largest segment | Diagnostics |
Fastest growing segment | Therapeutics |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Diagnostics, Therapeutics |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Jubilant Pharmova, Nordion, Bracco, Iren SpA, Abliva AB, Lantheus Holdings Inc, Eckert & Ziegler Bebig SA, Mallinckrodt PLC Ordinary Shares - New, Cardinal Health Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to nuclear medicine market will help companies and investors design strategic landscapes.
Diagnostics was the largest segment with a revenue share of 71.6% in 2023. Horizon Databook has segmented the Europe nuclear medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
Europe holds the second largest share of the market owing to factors such as rising prevalence of cancer and growing geriatric population, which is highly susceptible to cardiovascular and neurological disorders.
In addition, introduction of new isotopes for diagnostic (Ga-67/Ge-68) and therapeutic (Sr-90/Y-90 or W188/Re-188) purposes is expected to accelerate market growth in Europe during the forecast period. Radioisotopes are widely used in Europe for the diagnosis and treatment of cancer, cardiovascular diseases, & others.
Nuclear medicine has shown major potential in the treatment of cancer and cardiovascular diseases. According to WHO, in Europe, approximately 3.7 million new cancer cases reported each year, making it the second leading cause of death and morbidity.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe nuclear medicine market , including forecasts for subscribers. This continent databook contains high-level insights into Europe nuclear medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account